Our Statement on COVID-19
Updated April 22, 2020
As the global COVID-19 pandemic continues to quickly evolve, Intercept remains committed to implementing measures intended to safeguard the health of our team and the patients we serve. In doing so, we are aiming to do our part to help slow the spread of COVID-19 in our communities and protect our employees and their families, all while continuing the critical work necessary to bring our approved medicines to people who need them.
Supporting Our Employees Across the Globe
In accordance with guidance issued by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and local authorities, Intercept’s global workforce, both office and field-based employees, are working remotely from home. We are leveraging digital communication technologies to continue important interactions with healthcare professionals, patients and other stakeholders.
Additionally, as a biotechnology company, many of our employees who are qualified health professionals are in a unique position to help in the battle against the virus. To support the increasing demand for medical workers, we have activated our global medical volunteer leave program to enable qualified employees to aid in this effort. Employees called to serve as medical volunteers from state health and governmental agencies, and others who are no longer practicing but want to volunteer with institutions in need can participate and will continue to receive their base salary and benefits while on leave. We applaud all who are called to duty to support this effort.
Providing Access to Our Medicines
As always, ensuring patient access to our medicines is of paramount importance, and we continue to work closely with our third-party manufacturers, distributors and other trusted partners to manage our supply chain activities and mitigate any potential disruptions to our OCALIVA® (obeticholic acid or OCA) supply as a result of COVID-19.
In the U.S., those seeking more information about treatment support for OCALIVA, may visit our Interconnect Support Services or contact 1 (844) 622-4278. Outside the U.S., those seeking such information may visit our Global Locations page for local contact information.
Working to Ensure the Safety and Integrity of Our Ongoing Clinical Trials
As a global organization with ongoing clinical trials being conducted around the world, we are monitoring the situation very closely and have taken measures intended to minimize any disruption to our trials. For example, we’re conducting remote site monitoring, transportation reimbursement and arranging additional shipments of investigational product to sites. Our major Phase 3 NASH studies, REGENERATE and REVERSE, are fully enrolled. We are focused first and foremost on patient safety and are working with our contract research organizations, study sites and other partners to ensure our studies continue to be conducted in a safe manner and that study integrity is maintained.
Focused on Maintaining Business Continuity
We remain focused on our strategic objectives for this year, which include the delivery of OCALIVA to appropriate patients, the ongoing regulatory review of our applications on file with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and our preparations for the launch of OCA for liver fibrosis due to nonalcoholic steatohepatitis (NASH) following approval.
Remaining Steadfast in Our Mission
More than ever, we remain steadfast in our mission to build a healthier tomorrow for patients with progressive non-viral liver diseases. We are tremendously grateful to our employees, customers, partners and other stakeholders who continue to demonstrate resolve and adaptability during this unprecedented time. We are committed to continuing to implement measures intended to minimize any potential business impact from COVID-19 and will continue to closely monitor, assess and respond to the situation as it evolves.
For additional information: